HMOX1 and glioblastoma: Clearly, HO-1 is extremely complex in terms of its tumorigenesis promotion and inhibition, but it may be a viable target for GBM treatment, that is, designing targeted inhibitor of HO-1 “dark” side based on its elevated expression in GBM.